Adjuvant CTX treatment as predictor of postsurgical disease-specific recurrences in 110 patients with PDAC, according to the extent of CD68-TAMs at the tumour–stroma interface
| CD68-TAM (%IRA)* | ||||||
|---|---|---|---|---|---|---|
| Low (first to third quartile) | High (fourth quartile) | |||||
| Recurrence rate (%) | HR (95% CI)† | p Value | Recurrence rate (%) | HR (95% CI)† | p Value | |
| Adjuvant chemotherapy treatment | ||||||
| No | 13/28 (46) | 2.19 (1.15 to 4.16) | 0.02 | 7/8 (88) | 0.38 (0.13 to 1.00) | 0.05 |
| Yes | 41/54 (76) | 11/20 (55) | ||||
*Densities as %IRA at the tumour invasive front.
†Cox regression analysis.
CTX, chemotherapy; %IRA, percentage immunoreactive area; PDAC, pancreatic ductal adenocarcinoma; TAMs, tumour-associated macrophages.